Navigation Links
The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
Date:5/14/2012

CAMBRIDGE, Mass. and SCHLIEREN-ZURICH, Switzerland, May 14, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig's disease).

(Photo: http://photos.prnewswire.com/prnh/20120514/DC05793)

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"Maintaining the health of motor neurons and their connections to muscles will be central in the effort to combat ALS. We are very pleased to be partnered with Neurotune on this important project and are eager for results," said Steve Perrin, Ph.D., CEO & CSO of ALS TDI. 

In ALS, motor neurons and their axons become disconnected from the muscle.  Maintaining connectivity at this "neuromuscular junction" is crucial to a person's ability to freely move, eat and breathe independently, all functions that are gradually lost as ALS progresses.  Neurotune has developed a novel class of compounds to maintain neuromuscular junction strength and stability. Under the terms of the agreement, ALS TDI will use one of those compounds in a preclinical model of ALS to determine if the treatment has an effect on disease course. 

"The collaboration with ALS TDI will allow Neurotune to have one of its most promising compounds developed for neuromuscular diseases tested in the ALS disease model. This might open new approaches in the treatment of ALS," emphasizes Armin Mader, Ph.D., CEO of Neurotune.

About ALS

Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that leads to paralysis, due to the death of motor neurons in the spinal cord and brain. There is no known cause, cure or effective treatment for the disease. About 5,000 people in the U.S. are diagnosed with ALS each year; the incidence is similar to Multiple Sclerosis. However, with no effective treatment and an aggressive and rapid disease progression, the average patient survives only 2-5 years following their diagnosis. There are about 30,000 U.S. citizens diagnosed with the disease at any given time. The worldwide population of ALS patients is estimated at 400,000.

About the ALS Therapy Development Institute (ALS TDI)

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) as soon as possible for patients today. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world's largest efforts to preclinically validate potential therapeutics; including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech institute, ALS TDI has developed an industrial-scale platform, employs 30 professional scientists and evaluates dozens of potential therapeutics each year. ALS TDI collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, Aestus Therapeutics, MDA and RGK Foundation. ALS TDI is a 501(c)3 registered charitable nonprofit organization. For more information, please visit us online at www.als.net

About Neurotune AG (www.neurotune.com)

Neurotune develops medications to treat disorders of the human nervous system and is developing treatments, which modulate (tune) the connections between nerve cells and their target cells. The Company is developing a strong pipeline of drugs targeting large, growing markets where there is significant unmet medical need, including chronic pain and sarcopenia, the age-related loss of muscle mass which will affect over 3% of the total world population by 2015. Neurotune employs a strong multi-disciplinary team. It was incorporated in January 2005 and is domiciled in Schlieren-Zurich, Switzerland.

Media Contact: Mari Sullivan, ALS TDI, msullivan@als.net, 617-441-7220


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
8. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 ... across 154 pages, profiling 09 key companies and ... a professional and in-depth study on the current ... basic overview of the industry including definitions, classifications, ... market analysis is provided for the international market ...
(Date:5/3/2016)... Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. Photo ... ... ... ... Sino-German High-Tech Fund (SGHF) is ...
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... endovascular medical technology, today announced Food and Drug ... cardiac resynchronization defibrillator that provides heart failure patients ... scans. Iperia devices also have remote monitoring with ... that adapts the heart rate in response to ...
Breaking Medicine Technology:
(Date:5/4/2016)... Lake Charles, LA (PRWEB) , ... May 04, 2016 , ... ... Lake Charles, LA area has teamed up with Big Brothers Big Sisters of Southwest ... are now being accepted here . , Big Brothers Big Sisters of Southwest ...
(Date:5/4/2016)... ... ... Wellness Center today announced its tenth anniversary of providing a complete approach to health ... to provide a holistic approach to wellness has now become a growing trend of ... Chiropractic Physician , the wellness center offers a complete range of services such as ...
(Date:5/4/2016)... East Providence, Rhode Island (PRWEB) , ... May ... ... website was launched in April 2016. SS&A teamed up with one of the ... website. This legal information portal contains informative legal articles related to the law ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... that is transforming breastfeeding for nursing mothers. The company’s patented technology, The Smart ... breastfeeding. Today, the company announced that the technology is now available for purchase ...
(Date:5/4/2016)... Louis, MO (PRWEB) , ... May 04, 2016 , ... ... its newly launched health brand, Verywell, have tapped David Katz, MD, MPH, ... , “Our shared devotion to lifestyle medicine is especially gratifying,” said Katz. ...
Breaking Medicine News(10 mins):